Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.43 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.43 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18009901 | 1.00 | PRMT6 (0.44) | PRMT6PRMT5WDR77PI4KAPI4K2B | |
| SCHEMBL22435074 | 0.94 | PRMT6 (0.45) | PRMT6PRMT5WDR77PI4KAPI4K2B | |
| SCHEMBL19344404 | 0.94 | PRMT6 (0.45) | PRMT6PRMT5WDR77PI4KAPI4K2B | |
| SCHEMBL14113287 | 0.87 | P2RY12 (0.54) | ADORA2AADORA2BP2RY12 | |
| SCHEMBL18009928 | 0.86 | P2RY12 (0.47) | PRMT6PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL14113328 | 0.85 | P2RY12 (0.45) | PI4KAPI4K2BPI4K2API4KBP2RY12 | |
| SCHEMBL22601403 | 0.85 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL22402681 | 0.85 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL29444514 | 0.85 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL16378775 | 0.85 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | TYMP, NME1, DPYD | PRMT6 1736/4885PRMT5 1543/4885WDR77 2428/4885 |
| US-20160244475-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | TYMP, NME1, PNP | PRMT6 1741/4885PRMT5 1552/4885WDR77 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.